Immunoassay for the qualitative determination of antibodies to Trypanosoma cruzi
Chagas disease is caused by the flagellated protozoan parasite Trypanosoma cruzi (T. cruzi).1 It can be transmitted by hematophagous triatomine insects in endemic areas, by infected blood components, organ transplantations, congenitally from mother to infant and by ingestion of contaminated food.1
T. cruzi is found in the Americas, and has also become an issue in Canada, USA, several countries in Europe, and elsewhere, including Japan and Australia.2,3,4 It is estimated that 6 - 7 million people are infected with T. cruzi worldwide and 20 to 30% of these develop symptomatic, potentially life-threatening Chagas cardiomyopathy and gastrointestinal disease.5
A positive serology is considered as a sign of active T. cruzi infection or past exposure.6 The Elecsys® Chagas assay uses recombinant antigens for the determination of antibodies to T. cruzi.
* 1 (out of 204) Malaria positive samples was found positive with Elecsys Chagas. 6 additional samples (Dengue: 5/Leishmaniosis: 1) were excluded from the table. These samples were from Chagas endemic regions and were found reactive in the Elecsys Chagas assay as well as in at least one additional Chagas antibody assay.